menu
    • menu
    [{"orgOrder":0,"company":"Protomer Technologies","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Glucose Responsive Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Protomer Technologies","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Protomer Technologies \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Protomer Technologies \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Protomer Technologies

    Menu

    Protomer Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Protomer Technologies

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Protomer Technologies

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucose Responsive Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Announces Acquisition of Protomer Technologies

                            Details : Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            July 14, 2021

                            Lead Product(s) : Glucose Responsive Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth